Bilcare Limited Announces Director Changes and Board Committee Reconstitution

2 min read     Updated on 25 Apr 2026, 11:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Bilcare Limited announced the cessation of Mrs. Madhuri Vaidya as Independent Director effective April 26, 2026, upon completion of her second five-year term. The Board appointed Advocate Ashwini Ashok Hasabnis as Non-Executive Independent Woman Director for five years from April 25, 2026, subject to shareholder approval. The company also reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee effective April 25, 2026.

powered bylight_fuzz_icon
38686874

*this image is generated using AI for illustrative purposes only.

Bilcare Limited has announced key changes to its board composition and committee structure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that Mrs. Madhuri Vaidya (DIN: 08483512) will cease to hold the position of Independent Director upon completion of her second term at the close of business hours on April 26, 2026. Mrs. Vaidya was initially appointed for her second five-year term effective from April 26, 2021. The Board of Directors and Management expressed their appreciation for her valuable contributions during her tenure as an Independent Director.

In a related development, the Board of Directors, based on recommendations from the Nomination & Remuneration Committee, approved the appointment of Advocate Ashwini Ashok Hasabnis (DIN: 7766525) as an Additional Director in the category of Non-Executive Independent Woman Director. The appointment is for a first term of five consecutive years effective from April 25, 2026, subject to approval by the shareholders. The company confirmed that Advocate Hasabnis has not been debarred from holding the office of Director by any order from SEBI or other authorities. Shareholder approval will be sought through Postal Ballot or General Meeting, with details to be communicated in due course.

Advocate Ashwini Ashok Hasabnis brings over two decades of legal experience to the role. She holds a B.A., LL.B. degree and is enrolled with the Bar Council of Maharashtra and Goa. Her specialization includes civil and consumer law matters, arbitration proceedings, banking and finance-related disputes, and legal documentation. She has served as a legal advisor to corporates and banking institutions, providing guidance on contractual matters, documentation, and regulatory compliance.

The Board has also approved the reconstitution of three key committees effective from April 25, 2026. The Audit Committee will be chaired by Mr. Rajesh Devene (Independent Director), with Adv. Ashwini Hasabnis (Independent Director) and Mr. Shreyans Bhandari as members. The Nomination and Remuneration Committee will also be chaired by Mr. Rajesh Devene, with Ms. Alka Sagar (Independent Director) and Adv. Ashwini Hasabnis (Independent Director) serving as members. The Stakeholders Relationship Committee composition includes Mr. Rajesh Devene as Chairperson (Independent Director), Ms. Alka Sagar (Independent Director), and Mr. Shreyans Bhandari as members.

Director Appointment Details

Particulars Details
Name Advocate Ashwini Ashok Hasabnis
DIN 7766525
Category Non-Executive Independent Woman Director
Appointment Date 25 April 2026
Term Five years subject to shareholders approval
Qualification B.A., LL.B.
Experience Over two decades in legal practice

Board Committee Composition (Effective 25 April 2026)

Committee Chairperson Members
Audit Committee Mr. Rajesh Devene Adv. Ashwini Hasabnis, Mr. Shreyans Bhandari
Nomination and Remuneration Committee Mr. Rajesh Devene Ms. Alka Sagar, Adv. Ashwini Hasabnis
Stakeholders Relationship Committee Mr. Rajesh Devene Ms. Alka Sagar, Mr. Shreyans Bhandari

Historical Stock Returns for Bilcare

1 Day5 Days1 Month6 Months1 Year5 Years
+5.61%-0.94%-0.94%-0.94%-0.94%-0.94%

How might Advocate Hasabnis's legal expertise in banking and finance disputes influence Bilcare's strategic decisions regarding regulatory compliance and risk management?

What impact could the board restructuring have on Bilcare's corporate governance ratings and investor confidence in the pharmaceutical packaging sector?

Will the new independent director's specialization in arbitration and corporate advisory services signal potential changes in Bilcare's approach to business partnerships or dispute resolution?

Bilcare Limited Files SEBI Compliance Certificate for Quarter Ended March 31, 2026

1 min read     Updated on 16 Apr 2026, 08:57 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Bilcare Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, filed through the Bombay Stock Exchange on April 16, 2026. The certificate from registrar MUFG Intime India Private Limited confirms proper processing of dematerialisation requests and adherence to prescribed timelines for securities conversion during the quarter.

powered bylight_fuzz_icon
37898872

*this image is generated using AI for illustrative purposes only.

Bilcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical packaging company submitted the mandatory certificate to the Bombay Stock Exchange on April 16, 2026.

Regulatory Compliance Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as Bilcare's registrar and share transfer agent. The filing confirms compliance with SEBI's dematerialisation requirements for the quarter.

Parameter: Details
Filing Date: April 16, 2026
Quarter Covered: Ended March 31, 2026
Regulation: SEBI Regulation 74(5)
Registrar: MUFG Intime India Private Limited
SEBI Registration: INR000004058

Certificate Confirmation

MUFG Intime India Private Limited confirmed in its certificate dated April 6, 2026 that all securities received from depository participants for dematerialisation during the quarter were properly processed. The registrar verified that:

  • Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
  • All security certificates were mutilated and cancelled after due verification
  • Depository names were substituted in the register of members as registered owners
  • Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed

Company Information

Bilcare Limited, headquartered at 301 Kamal Kunj, 8 Shivaji Housing Society, Pune 411016, operates in the pharmaceutical packaging sector. The company maintains its registrar services through MUFG Intime India Private Limited, located at Block No 202, 2nd Floor, Akshay Complex, Off Dhole Patil Road, Pune.

Regulatory Framework

Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 mandates quarterly certification from registrar and share transfer agents regarding dematerialisation processes. This ensures transparency and compliance in the conversion of physical securities to electronic form, protecting investor interests in the capital markets.

Historical Stock Returns for Bilcare

1 Day5 Days1 Month6 Months1 Year5 Years
+5.61%-0.94%-0.94%-0.94%-0.94%-0.94%

How might Bilcare's pharmaceutical packaging business be positioned to benefit from India's growing generic drug manufacturing sector in 2026?

What impact could MUFG's rebranding from Link Intime have on registrar services efficiency for mid-cap pharmaceutical companies?

Will increased digitalization trends post-2025 accelerate dematerialization rates for smaller pharmaceutical sector stocks?

More News on Bilcare

1 Year Returns:-0.94%